TY - JOUR
T1 - Design of multifunctional peptides expressing both antimicrobial activity and shiga toxin neutralization activity
AU - Yamada, Yoshinao
AU - Miura, Yoshiko
AU - Sakaki, Akio
AU - Yoshida, Tetsuhiko
AU - Kobayashi, Kazukiyo
PY - 2006/1/1
Y1 - 2006/1/1
N2 - We have designed novel short peptides expressing both antimicrobial and Shiga-toxin (Stx) neutralization activities by combining nuclear localization signal (NLS) peptides (RIRKKLR, PKKKRKV, and PRRRK) tandemly with globotriaoside (Gb3) mimic peptide (WHWTWL). These fusion peptides exhibited excellent antimicrobial activity against both gram-positive and gram-negative bacteria. A peptide WHWTWLRIRKKLR (Trp-His-Trp-Thr-Trp-Leu-Arg-Ile-Arg-Lys-Lys-Leu-Arg), especially, exhibited about 100 times higher activity than the original NLS peptide. SPR analysis demonstrated that the binding of this peptide to both Stxs was strong: Kd = 6.6 × 10-6 to Stx-1 and 6.8 × 10-6 to Stx-2. The in vitro assay against Stx-1 using HeLa cells showed that this peptide increased the survival rate of HeLa cells against the infection of Stx-1. The peptide has been found to maintain high antimicrobial activity, Stx neutralization activity, and no cytotoxicity at its concentration of 7.8-31.3 μg/mL (4.2-16.7 μM). The present peptide design has a prospect of developing potent multifunctional drugs to destroy proteinaceous toxin-producing bacteria and to simultaneously neutralize the toxins released by bacteriolysis.
AB - We have designed novel short peptides expressing both antimicrobial and Shiga-toxin (Stx) neutralization activities by combining nuclear localization signal (NLS) peptides (RIRKKLR, PKKKRKV, and PRRRK) tandemly with globotriaoside (Gb3) mimic peptide (WHWTWL). These fusion peptides exhibited excellent antimicrobial activity against both gram-positive and gram-negative bacteria. A peptide WHWTWLRIRKKLR (Trp-His-Trp-Thr-Trp-Leu-Arg-Ile-Arg-Lys-Lys-Leu-Arg), especially, exhibited about 100 times higher activity than the original NLS peptide. SPR analysis demonstrated that the binding of this peptide to both Stxs was strong: Kd = 6.6 × 10-6 to Stx-1 and 6.8 × 10-6 to Stx-2. The in vitro assay against Stx-1 using HeLa cells showed that this peptide increased the survival rate of HeLa cells against the infection of Stx-1. The peptide has been found to maintain high antimicrobial activity, Stx neutralization activity, and no cytotoxicity at its concentration of 7.8-31.3 μg/mL (4.2-16.7 μM). The present peptide design has a prospect of developing potent multifunctional drugs to destroy proteinaceous toxin-producing bacteria and to simultaneously neutralize the toxins released by bacteriolysis.
UR - http://www.scopus.com/inward/record.url?scp=27744600137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27744600137&partnerID=8YFLogxK
U2 - 10.1016/j.bmc.2005.07.052
DO - 10.1016/j.bmc.2005.07.052
M3 - Article
C2 - 16169733
AN - SCOPUS:27744600137
SN - 0968-0896
VL - 14
SP - 77
EP - 82
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
IS - 1
ER -